Ziskavit

Ziskavit is indicated for:

• Established use: Prevention and treatment of B-vitamin deficiency states (e.g., deficiency of thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, and cobalamin), including conditions such as beriberi, angular stomatitis, glossitis, and peripheral neuritis related to B-vitamin deficiency.
• Guideline-supported / general nutritional support: Dietary supplementation for individuals with inadequate dietary intake, increased metabolic requirements (e.g., pregnancy, lactation, growth periods, convalescence after illness or surgery), or increased losses.
• Adjunct use: Supportive therapy in malabsorption syndromes, chronic gastrointestinal disorders, chronic alcoholism, and prolonged febrile illness, where B-vitamin depletion is common, as an adjunct to treatment of the underlying condition.
• Common off-label/supplemental use: General supplementation for fatigue, loss of appetite, and support of nervous system and energy metabolism, although evidence for benefit in individuals without an underlying deficiency is limited.

Ziskavit is not a substitute for treatment of the underlying cause of a nutritional deficiency, and it does not treat conditions unrelated to B-vitamin status.

Vitamin B complex typically contains a combination of water-soluble B-vitamins, which commonly include:

• Thiamine (Vitamin B1)
• Riboflavin (Vitamin B2)
• Niacin/Niacinamide (Vitamin B3)
• Pantothenic acid (Vitamin B5)
• Pyridoxine (Vitamin B6)
• Biotin (Vitamin B7)
• Folic acid (Vitamin B9)
• Cyanocobalamin/Methylcobalamin (Vitamin B12)

Exact strengths and the specific vitamins included vary by brand and formulation (tablet, capsule, syrup, or injection); refer to the product label for the exact composition of a specific brand of Vitamin B complex.

Ziskavit is a multivitamin preparation combining several water-soluble B-group vitamins that function as essential cofactors in cellular energy metabolism, nervous system function, and red blood cell formation. The B-vitamins in Ziskavit are not stored in the body in large amounts and must be replenished regularly through diet or supplementation.

Ziskavit is available in various dosage forms including tablets, capsules, oral syrup, and injectable solutions, and is widely used both for treating diagnosed deficiency states and as general nutritional support.

Ziskavit belongs to the therapeutic class of Vitamin B-complex preparations / multivitamin (water-soluble vitamin) supplements.

Vitamin B complex supplies multiple B-group vitamins, each with a distinct physiological role:

• Thiamine (B1): Cofactor for carbohydrate metabolism (as thiamine pyrophosphate) and normal nerve conduction.
• Riboflavin (B2): Precursor of FAD and FMN, essential for cellular oxidation-reduction reactions.
• Niacin (B3): Precursor of NAD and NADP, involved in energy production and lipid metabolism.
• Pantothenic acid (B5): Component of coenzyme A, required for fatty acid metabolism.
• Pyridoxine (B6): Cofactor in amino acid metabolism and neurotransmitter synthesis.
• Biotin (B7): Cofactor for carboxylase enzymes in fat and carbohydrate metabolism.
• Folic acid (B9): Required for DNA synthesis and red blood cell maturation.
• Cobalamin (B12): Required for DNA synthesis, myelin formation, and red blood cell production, working closely with folic acid.

Collectively, the vitamins in Vitamin B complex support energy metabolism, maintenance of the nervous system, and normal hematopoiesis (red blood cell formation).

Oral forms of Ziskavit (tablets, capsules, syrup) should preferably be taken with or after meals to minimize gastrointestinal discomfort, and swallowed with a full glass of water. Syrup should be measured using a proper measuring device. Injectable forms of Ziskavit must be administered by a qualified healthcare professional via intramuscular or slow intravenous injection; rapid intravenous administration should be avoided, and undiluted injections should be given slowly to reduce injection-site pain.

Ziskavit has the following well-recognized clinically significant interactions:

• Levodopa: Pyridoxine (Vitamin B6) can reduce the therapeutic effect of levodopa (when used without a decarboxylase inhibitor such as carbidopa) in Parkinson's disease by increasing its peripheral metabolism; concurrent use of Ziskavit with levodopa alone should be avoided or supervised by a physician.
• Phenytoin, phenobarbital, primidone: Folic acid in Ziskavit may reduce serum concentrations of these anticonvulsants, potentially reducing seizure control; monitoring is advised with concurrent use.
• Isoniazid, hydralazine, penicillamine: These drugs can increase the requirement for pyridoxine (Vitamin B6); Ziskavit is sometimes used to offset this effect under medical guidance.
• Chloramphenicol: May antagonize the hematologic response to Vitamin B12 in Ziskavit.

Patients should inform their physician of all medications being taken before starting Ziskavit.

Ziskavit is generally well tolerated at standard supplement doses. Reported side effects include:

• Mild gastrointestinal upset (nausea, stomach discomfort), especially if taken on an empty stomach
• Harmless bright yellow discoloration of urine (due to riboflavin)
• Injection-site pain or, rarely, allergic reactions with injectable forms
• Rarely, high-dose or prolonged use of pyridoxine (Vitamin B6) has been associated with peripheral neuropathy (see Precautions and Warnings)
• Rare hypersensitivity reactions (skin rash, itching; anaphylaxis has been rarely reported with parenteral thiamine)

Standard supplemental doses of Ziskavit are generally considered safe during pregnancy and lactation and are often beneficial, particularly the folic acid component, which supports fetal neural tube development. However, Ziskavit should be used only as directed, and doses above the standard recommended supplemental amount should be used only if clearly needed and the potential benefit justifies the potential risk; a physician should be consulted before use, especially at higher-than-standard doses, to individualize therapy during pregnancy or breastfeeding.

The following precautions apply to the use of Ziskavit:

• Pyridoxine (B6) neuropathy: High-dose, prolonged supplementation with pyridoxine has been associated, in rare cases, with sensory peripheral neuropathy; avoid exceeding recommended doses for prolonged periods without medical supervision.
• Masking of Vitamin B12 deficiency: Folic acid supplementation can correct the megaloblastic anemia caused by Vitamin B12 deficiency while allowing underlying neurological damage from B12 deficiency to progress unrecognized; if anemia is suspected, proper evaluation of B12 status is advisable before or during use of Ziskavit.
• Levodopa therapy: Use with caution in patients on levodopa alone (see Interactions).
• Injectable forms: Rare hypersensitivity/anaphylactoid reactions have been reported with parenteral thiamine-containing products; administer injections slowly and under appropriate medical supervision.

Ziskavit is not an antibiotic and does not require antimicrobial stewardship precautions; however, it should still be taken as directed by a physician or pharmacist.

Significant toxicity from oral Ziskavit at recommended doses is uncommon because most B-vitamins are water-soluble and excess amounts are excreted in urine; however, very high or prolonged doses (particularly of pyridoxine/B6 or niacin) may cause adverse effects such as peripheral neuropathy or flushing and liver effects, respectively. In case of a suspected overdose of Ziskavit, or if the patient develops symptoms such as severe nausea, numbness/tingling, or an allergic reaction after an injection, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Injectable forms should be protected from light and stored as per the specific product's labeling.

Pediatric use: Ziskavit may be used in children for prevention/treatment of B-vitamin deficiency using age-appropriate, weight-based dosing and formulations (typically syrup for younger children); dosing should be individualized by a pediatrician, and safety/efficacy of high-dose regimens or specific combination strengths in young children has not been formally established for all products.

Elderly: No specific dose adjustment is generally required, but elderly patients with renal impairment or those on multiple medications should use Ziskavit under medical supervision due to potential interactions and altered vitamin handling.

Renal impairment: Patients with significant renal impairment may have reduced clearance of water-soluble vitamins; use Ziskavit cautiously and under medical guidance in this population.

Hepatic impairment: No well-established dose adjustment is required for standard supplemental doses of Ziskavit, but high-dose niacin should be used cautiously in patients with liver disease.

The duration of treatment with Ziskavit depends on the indication. For correction of a diagnosed deficiency, treatment is usually continued for several weeks to a few months, or until deficiency is corrected and confirmed by clinical improvement or laboratory testing, as advised by a physician. For general nutritional supplementation, Ziskavit may be used for longer periods as part of a maintenance regimen, but prolonged high-dose use (especially of pyridoxine) should be avoided without medical supervision. Follow the physician's advice regarding how long to continue treatment.

Vitamin B-complex / multivitamin (water-soluble B-vitamin) supplement

Vitamin B complex works by replenishing the water-soluble B-group vitamins that act as essential coenzymes and cofactors in numerous metabolic pathways, including carbohydrate, fat, and amino acid metabolism (energy production), nucleic acid synthesis, and maintenance of nerve cell function and myelin integrity. By restoring adequate levels of these vitamins, Vitamin B complex helps normalize these metabolic processes in individuals who are deficient or at risk of deficiency, and supports normal red blood cell formation and nervous system function.

Ziskavit can be used in pediatric patients for prevention and treatment of B-vitamin deficiency, typically using oral syrup or age-appropriate low-strength tablet formulations dosed according to age and body weight, under the guidance of a pediatrician. Safety and efficacy of specific high-strength combination products or injectable forms in infants and young children have not been formally established for all brands, and such use should be individualized and supervised by a physician.